Rosalind Advisors’s CorMedix CRMD Stock Holding History

Rosalind Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,475,000	Closed	-$14.7M	–	44
2024 Q3	$11.9M	Buy	+1,475,000	New	+$7.98M	7.63%	3

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Rosalind Advisors's CRMD Position: Q4 2024 in Review

Rosalind Advisors sold out of CorMedix (CRMD) in Q4 2024, closing a stake of 1,475,000 shares — an estimated $14.7M sold.

Rosalind Advisors first reported a position in CRMD in Q3 2024 and held it in 1 quarter. The position peaked at $11.9M in Q3 2024. 129 funds tracked by Wall St. Rank hold CRMD as of Q4 2024.

Rosalind Advisors reported no remaining CorMedix position as of Q4 2024 after selling out during the quarter.
Rosalind Advisors sold 1,475,000 CorMedix shares in Q4 2024, an estimated $14.7M.
Rosalind Advisors first reported a position in CorMedix in Q3 2024 and held it in 1 quarter.
Rosalind Advisors's CorMedix position peaked at $11.9M in Q3 2024.
129 funds tracked by Wall St. Rank held CorMedix as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.